Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2006-04-20 Capital/Financing Update
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2006
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for the offering of securities by XTL Biopharmaceuticals Ltd., including American Depositary Shares (ADSs). The text includes detailed information about the offering, company background, risk factors, use of proceeds, share capital, and other disclosures typical of a registration statement prospectus. It is not an annual report, earnings release, or any other type of financial report but rather a capital markets filing related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or certification, supporting high confidence in this classification.
2006-04-20 English
Capital/Financing Update 2006
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces a private equity transaction raising $28 million through the issuance of shares and warrants. The content focuses on the financing event, details of the private placement, and related information about the company and its drug pipeline. There are no financial statements or detailed financial performance data included, only an announcement of a capital raise. The document length is 7,387 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase "raises $28 million in private equity transaction" and the description of the transaction indicate this is a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2006-03-22 English
Interim / Quarterly Report 2006
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd., a foreign private issuer. It announces the company's financial results for the year ended December 31, 2005, including detailed financial statements such as consolidated balance sheets, statements of operations, and cash flows. The document also discusses a private placement financing and provides management commentary on the company's operations and outlook. The presence of comprehensive financial data and the nature of the filing (Form 6-K) indicate this is an interim or periodic financial report for a period shorter than a full fiscal year, but it contains substantive financial data and analysis. Therefore, the document fits best under the category of Interim / Quarterly Report (IR).
2006-03-22 English
Report of Periodic or Interim Report
Regulatory Filings
2006-03-21 Hebrew (modern)
Report of Periodic or Interim Report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli regulations. It then specifies the content being attached: '*Financial Results for the year ended 31 December, 2005*'. Since this covers a full fiscal year (ended December 31, 2005), it strongly suggests an Annual Report. However, the document structure is very brief, contains metadata, and explicitly states 'Attached hereto is a report on...' followed by a filename ('04-06Financials_20_Mar_06_isa.pdf'). This structure aligns perfectly with the 'MENU VS MEAL' rule, indicating this is an announcement about the release of the full report, not the report itself. If the full financial results for the year were attached, the code would be 10-K. Since this is an announcement of the publication of the annual financial results, it fits best as a Report Publication Announcement (RPA) or potentially a Regulatory Filing (RNS) if RPA is too specific. Given the explicit mention of publishing a report, RPA is the most precise fit, as it signals the availability of the main document.
2006-03-21 English
Immediate report on other matter
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private equity financing transaction where XTL Biopharmaceuticals Ltd. raised $28 million through a private placement of ordinary shares and warrants. It details the transaction terms, the use of proceeds, and includes forward-looking statements and disclaimers. There is no financial statement data, no regulatory filing form mentioned, and no indication that this is a full financial report or earnings release. The content focuses on capital raising and financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is about 5795 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2006-03-20 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.